Q32 Bio (NASDAQ:QTTB) Insider Shelia Violette Sells 2,815 Shares

February 28, 2026 by InsiderTrades.com

Key Points

CEO insider sale: Q32 Bio CEO Jodie Pope Morrison sold 9,896 shares on Feb. 25 at an average price of $4.51 for roughly $44,631, trimming her holding by 10% to 89,104 shares (≈$401,859); she also sold 22,506 shares in December.
Analyst and market backdrop: HC Wainwright began coverage with a Buy and a $13 price target, but consensus sentiment is mixed (average "Hold") and analysts project substantial near‑term losses, increasing financing and execution risk for the company.

Q32 Bio Inc. (NASDAQ:QTTB - Get Free Report) insider Shelia Violette sold 2,815 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $4.51, for a total transaction of $12,695.65. Following the sale, the insider directly owned 55,569 shares in the company, valued at approximately $250,616.19. This represents a 4.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Q32 Bio Price Performance

Shares of QTTB stock traded down $0.20 during trading hours on Friday, reaching $4.56. 203,990 shares of the company were exchanged, compared to its average volume of 149,267. Q32 Bio Inc. has a fifty-two week low of $1.35 and a fifty-two week high of $6.37. The stock's fifty day moving average is $3.81 and its two-hundred day moving average is $2.90. The company has a market cap of $56.11 million, a price-to-earnings ratio of -1.33 and a beta of 0.16.

Institutional Investors Weigh In On Q32 Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of QTTB. Opaleye Management Inc. bought a new stake in shares of Q32 Bio in the fourth quarter worth $708,000. Monaco Asset Management SAM grew its position in Q32 Bio by 17.1% in the second quarter. Monaco Asset Management SAM now owns 591,937 shares of the company's stock valued at $882,000 after purchasing an additional 86,486 shares in the last quarter. Renaissance Technologies LLC increased its stake in Q32 Bio by 110.6% in the 4th quarter. Renaissance Technologies LLC now owns 99,600 shares of the company's stock valued at $331,000 after buying an additional 52,300 shares during the last quarter. Jane Street Group LLC acquired a new stake in Q32 Bio in the 2nd quarter valued at $69,000. Finally, AQR Capital Management LLC bought a new stake in Q32 Bio during the 1st quarter worth about $68,000. Institutional investors and hedge funds own 31.32% of the company's stock.

Key Q32 Bio News

Here are the key news stories impacting Q32 Bio this week:

Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. HC Wainwright initiated coverage on Q32 Bio in a research report on Wednesday. They issued a "buy" rating and a $13.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Q32 Bio in a research note on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $14.00.

Get Our Latest Stock Analysis on QTTB

Q32 Bio Company Profile

(Get Free Report)

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.